Timothy Coté
Directeur Général chez Coté Orphan LLC
Fortune : 10 810 $ au 30/04/2024
Profil
Timothy R.
Coté is the founder of Coté Orphan LLC.
He worked as a Director at Soligenix, Inc. in 2023.
Prior to that, he was a Non-Executive Director at Xenetic Biosciences (UK) Ltd.
and Xenetic Biosciences, Inc. Dr. Coté received his undergraduate degree from Syracuse University, his doctorate from Howard University, and his graduate degree from Harvard T.H.
Chan School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SOLIGENIX, INC.
0,18% | 03/05/2023 | 25 317 ( 0,18% ) | 10 810 $ | 30/04/2024 |
Postes actifs de Timothy Coté
| Sociétés | Poste | Début |
|---|---|---|
Coté Orphan LLC
 Coté Orphan LLC Miscellaneous Commercial ServicesCommercial Services Coté Orphan LLC is a boutique full-service regulatory group with a laser focus on Orphan Drugs. Its services include FDA orphan designation, EMA orphan designation, strategic reviews, IND filings and NDA, BLA and MAA filings. The company was founded by Timothy R. Cote and is headquartered in Silver Spring, MD. | Directeur Général | - |
Anciens postes connus de Timothy Coté
| Sociétés | Poste | Fin |
|---|---|---|
| SOLIGENIX, INC. | Directeur/Membre du Conseil | 07/07/2023 |
Xenetic Biosciences (UK) Ltd.
 Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | - |
| XENETIC BIOSCIENCES, INC. | Directeur/Membre du Conseil | - |
Formation de Timothy Coté
| Syracuse University | Undergraduate Degree |
| Howard University | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SOLIGENIX, INC. | Health Technology |
| XENETIC BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Coté Orphan LLC
Coté Orphan LLC Miscellaneous Commercial ServicesCommercial Services Coté Orphan LLC is a boutique full-service regulatory group with a laser focus on Orphan Drugs. Its services include FDA orphan designation, EMA orphan designation, strategic reviews, IND filings and NDA, BLA and MAA filings. The company was founded by Timothy R. Cote and is headquartered in Silver Spring, MD. | Commercial Services |
